Inside Drug Pricing: IRA Suits Dismissed Back-To-Back By Two Appeals Courts

Patients for Affordable Drugs and other advocates for federal drug pricing reform are pleased with the back-to-back appellate decisions. The BI ruling further emphasizes that pharmaceutical companies cannot claim constitutional violations because they are opposed to the terms of doing business with the government, the advocates said.

“It’s the U.S. versus Pharma, and today’s decision is another clear win for patients. The ruling affirms what we’ve known all along: Big Pharma’s legal arguments are baseless, and their scare tactics are failing. Medicare negotiation is set to deliver lower prices to more than 9 million patients across the nation in less than six months, and the popular program is standing strong against the industry’s legal attacks. Pharma hired some of the most expensive lawyers in the world to block this program, and they’ve lost yet again,” P4AD Executive Director Merith Basey said in a statement Thursday.